Takafumi Yanagisawa, Kenichi Hata, Shintaro Narita, Shingo Hatakeyama, Keiichiro Mori, Yuji Yata, Takayuki Sano, Takashi Otsuka, Shuhei Hara, Keiichiro Miyajima, Yuki Enei, Wataru Fukuokaya, Minoru Nakazono, Akihiro Matsukawa, Jun Miki, Tomonori Habuchi, Chikara Ohyama, Shahrokh F Shariat, Takahiro Kimura
PURPOSE: We aimed to assess the oncologic efficacy of combining docetaxel (DOC) versus abiraterone (ABI) with androgen deprivation therapy (ADT) in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with a focus on the efficacy of sequential therapy, in a real-world clinical practice setting. METHODS: The records of 336 patients who harbored de novo high-risk mHSPC, based on the LATITUDE criteria, and had received ADT with either DOC (n = 109) or ABI (n = 227) were retrospectively analyzed...
May 2023: Prostate